| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC11206 | HSD-016 Featured | HSD-016 (HSD016) is a potent, selective, and efficacious 11β-HSD1 inhibitor with IC50 of 149 and 530 nM for mouse and human 11β-HSD1, respectively. |
|
| DC11207 | INCB13739 Featured | INCB13739 (INCB-13739) is a potent, selective, oral 11βHSD1 inhibitor (IC50=1.1 nM) with high seelctivity over other dehydrogenases, glucocorticoid and mineralocorticoid receptors.. |
|
| DC11522 | Imarikiren hydrochloride | A highly potent, selective, orally active renin inhibitor with IC50 of 2.1 nM in hPRA assay. |
|
| DC11933 | RX 871024 | A imidazoline compound that stimulate insulin release by inhibition of ATP-dependent K+ channels and inducing of Ca2+ mobilization in mouse pancreatic beta-cells. |
|
| DC11536 | Imigliptin dihydrochloride | A novel potent, selective, orally available DPP-4 inhibitor with IC50 of 9 nM. |
|
| DC11898 | Gosogliptin | A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM. |
|
| DC11899 | Gosogliptin dihydrochloride | A potent, selective, competitive, orally active dipeptidyl peptidase-4 (DPP-4) inhibitor with IC50 of 13 nM. |
|
| DC7045 | A-769662 Featured | A-769662 is a potent, reversible AMPK activator with EC50 of 0.8 μM, little effect on GPPase/FBPase activity. |
|
| DCAPI1034 | Alendronate (Fosamax) | Alendronate (Fosamax) |
|
| DC9830 | AM-2394 Featured | AM-2394 is a potent and selective Glucokinase agonist (GKA), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. |
|
| DC11809 | APX-115 Featured | APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively. |
|
| DC11174 | ASP7657 Featured | ASP7657 (ASP-7657) is a potent, selective, orally active prostaglandin EP4 receptor antagonist with Ki values of 6.02 nM and 2.21 nM for rat and human EP4 receptors, resepctively. |
|
| DC11032 | AZD9977 Featured | AZD9977 is a first-in-class, potent, selective, mineralocorticoid receptor (MR) modulator with IC50 of 0.37. 0.08 and 0.08 uM for human, mouse and rat MR, respectively. |
|
| DC8160 | ZGN-440(Beloranib) | Beloranib is being studied as a first-in-class obesity therapy that demonstrates a unique mechanism of action through methionine aminopeptidase 2 (MetAP2 ) inhibition. |
|
| DC8186 | Bexagliflozin3 Featured | Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. |
|
| DC8571 | BGP-15 Featured | BGP-15 is a PARP inhibitor and insulin sensitizer. |
|
| DC11842 | BI 135585 | BI 135585 (BI-135585, BI135585) is a potent, selective, orally active 11β-HSD1 inhibitor with IC50 of 4.3 nM and 53 nM in human adipocytes and primary human adipose tissue, respectively. |
|
| DC11761 | BMS-816336 | A novel potent, selective, orally active human 11β-HSD1 inhibitor with IC50 of 3.0 nM. |
|
| DC8392 | BQ-123 Featured | BQ-123 is a selective endothelin A receptor (ETA) antagonist with IC50 of 7.3 nM. Phase 2. |
|
| DC8089 | BVT 2733(BVT.2733) Featured | BVT 2733 is a selective 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor,protecting osteoblasts against endogenous glucocorticoid induced dysfunction. |
|
| DC8278 | BVT-14225 Featured | BVT 14225 is a new selective 11b-HSD1 inhibitor, it belongs to a class of arylsulfonamidothiazoles with in vitro and in vivo antidiabetic effects |
|
| DCAPI1559 | Calcifediol Featured | Calcifediol is a major circulating metabolite of vitamin D3, acting as a competitive inhibitor with an apparent Ki of 3.9 μM, suppresses PTH secretion and mRNA (ED50=2 nM). |
|
| DC3111 | Canagliflozin Featured | Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively. |
|
| DC8482 | CAY10415(MSDC-0160) Featured | CAY10415 is a potent, antidiabetic drug of the TZD structural class. |
|
| DC10206 | CCX140 | CCX140 is a potent CCR2 antagonist. |
|
| DC6904 | DAPAGLIFLOZIN Featured | Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin. |
|
| DC8108 | DBPR108 | DBPR108 is a potent, selective, and orally bioavailable dipeptide-derived inhibitor of DPP4 with IC50 of 15 nM; no inhibition on DDP8 and DPP9. IC50 value: 15 Nm. |
|
| DC9414 | DGAT-1 inhibitor 2 | DGAT-1 inhibitor 2 is an effective inhibitor of DGAT-1;antiobesity agents. |
|
| DC11233 | DS-8500a | DS-8500a (DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells, displays no significant effect on 66 receptors, channels, or transporters. |
|
| DCAPI1356 | Epalrestat Featured | Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. |
|
